Clinical trial finds safe, effective treatment for children with severe post-Covid syndrome

pexels-cottonbro-5858841

Researchers have discovered that a drug designed to treat Celiac disease supported a more rapid return to normal activities for patients following COVID. A small, randomized clinical trialfound the oral drug larazotide was both safe and effective in treating children with MIS-C. 

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE